Clinical Trial Update: Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the maximum tolerable intravesical concentration of abnobaVISCUM Fraxini in patients with superficial bladder cancer has completed.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• abnobaVISCUM Fraxini (VISCUM fraxini (mistletoe extract))

Snippet

Sponsor: Abnoba Gmbh | Conditions: Superficial Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED